Fil d'Ariane

null Bertrand Jean-Claude, M.Sc., Ph. D.

Scientifique senior, IR-CUSM , site Glen

Programme de recherche en désordres métaboliques et leurs complications

Centre de biologie translationnelle

Professeur titulaire, Département de médecine, Faculté de médecine et des sciences de la santé, Université McGill

 

Mots-clés


Kinase inhibitors • anti-cancer drugs • pharmacokinetics • molecular modeling

Aire de recherche


Ma recherche porte sur la conception et la synthèse de nouveaux candidats en matière de médicaments destinés à bloquer les nombreuses voies des cellules tumorales.

Publications choisies


  • Qiu Q, Domarkas J, Banerjee R, Merayo N, Brahimi F, McNamee JP, Gibbs BF, Jean-Claude BJ. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin Cancer Res. 2007 Jan 1;13(1):331-40. PMID: 17200372.

  • Senhaji Mouhri Z, Goodfellow E, Kelley SP, Stein RS, Rogers RD, J Jean-Claude B. (15)N-, (13)C- and ¹H-NMR Spectroscopy Characterization and Growth Inhibitory Potency of a Combi-Molecule Synthesized by Acetylation of an Unstable Monoalkyltriazene. Molecules. 2017 Jul 19;22(7). pii: E1183. doi: 10.3390/molecules22071183. PMID: 28753938.

  • Todorova MI, Larroque AL, Dauphin-Pierre S, Fang YQ, Jean-Claude BJ. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Mol Cancer Ther. 2010 Apr;9(4):869-82. doi: 10.1158/1535-7163.MCT-09-0673. Epub 2010 Mar 30. PMID: 20354119.

  • Larroque-Lombard AL, Todorova M, Golabi N, Williams C, Jean-Claude BJ. Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5. J Med Chem. 2010 Mar 11;53(5):2104-13. doi: 10.1021/jm9016043. PMID: 20151639.

  • Rupp M, Mouhri ZS, Williams C, Jean-Claude BJ. Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O(6)-methylguanine-DNA methyltransferase with a double arm hybrid molecule. Oncotarget. 2018 Oct 12;9(80):35041-35055. doi: 10.18632/oncotarget.25120. eCollection 2018 Oct 12. PMID: 30416678.